JNJ
$235.37-2.23 (-0.94%)
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medi...
Recent News
Protagonist Therapeutics Soars as FDA Approves ICOTYDE for Plaque Psoriasis, Triggers $50M Milestone
Protagonist Therapeutics (NASDAQ:PTGX) executives said March 18 that the U.S. Food and Drug Administration has approved ICOTYDE for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kilograms and are candidates for s
Jim Cramer on Johnson & Johnson: “It’s a Textbook Slowdown Stock”
Johnson & Johnson (NYSE:JNJ) is one of the stocks mentioned during the show, as we cover everything Jim Cramer said about the oversold market. Cramer was quite bullish on the company’s stock, as he stated: Yesterday, we got some terrific news from Johnson & Johnson, but because the tape was so ugly, the stock did […]
Monte Rosa J J Supply Deal Refocuses MRT 2359 Prostate Cancer Story
Monte Rosa Therapeutics (NasdaqGS:GLUE) announced a new supply agreement with Johnson & Johnson to evaluate MRT-2359 with ERLEADA in metastatic castration resistant prostate cancer. The company is initiating a Phase 2 trial of the MRT-2359 plus ERLEADA combination in this setting. Additional positive clinical data for MRT-2359 in advanced prostate cancer were presented at ASCO GU 2026. Monte Rosa Therapeutics enters this news cycle with its shares at $15.63 and a 1 year return of 169.5%...
Protagonist Therapeutics Stock Rallies Nearly 7% in a Week: Here's Why
PTGX stock jumps as JNJ wins FDA nod for Icotyde in plaque psoriasis, unlocking milestone payments and royalty potential for Protagonist.
Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.